Phosphorus metabolism disorders


Phosphorus metabolism disorders are the result of abnormal serum phosphate levels. These abnormal levels are caused by defects in the intake, excretion and cellular utilization of phosphate. Hypophosphataemia is a low blood level of phosphate, whereas hyperphosphataemia describes high levels of phosphate in the blood.

Latest Research and Reviews

  • Reviews |

    Hypoparathyroidism is a disease characterized by inadequately low circulating levels of parathyroid hormone resulting in low calcium levels and increased phosphate levels in the blood. In this Primer, Mannstadt et al. summarize current knowledge of the prevalence, pathophysiology, clinical presentation and management of hypoparathyroidism.

    • Michael Mannstadt
    • , John P. Bilezikian
    • , Rajesh V. Thakker
    • , Fadil M. Hannan
    • , Bart L. Clarke
    • , Lars Rejnmark
    • , Deborah M. Mitchell
    • , Tamara J. Vokes
    • , Karen K. Winer
    •  & Dolores M. Shoback
  • Reviews |

    Tumour-induced osteomalacia (TIO), also known as oncogenic osteomalacia, is a rare paraneoplastic disorder caused by tumours that secrete fibroblast growth factor 23. Clinically, TIO is associated with hypophosphataemia and skeletal abnormalities. This Primer focuses on the epidemiological, pathophysiological, diagnostic and clinical aspects of TIO.

    • Salvatore Minisola
    • , Munro Peacock
    • , Seijii Fukumoto
    • , Cristiana Cipriani
    • , Jessica Pepe
    • , Sri Harsha Tella
    •  & Michael T. Collins
  • Reviews |

    Alkaline phosphatase (ALP) drives skeletal mineralization and has a role in vascular calcification and resulting cardiovascular disease in patients with CKD. Here, the authors describe the mechanisms of ALP-mediated vascular calcification and discuss the therapeutic potential of targeting ALP to improve cardiovascular outcomes in these patients.

    • Mathias Haarhaus
    • , Vincent Brandenburg
    • , Kamyar Kalantar-Zadeh
    • , Peter Stenvinkel
    •  & Per Magnusson
  • Reviews |

    Hyperphosphataemia is associated with poor clinical outcomes but strong evidence that targeting serum phosphate improves these outcomes is lacking. Here the authors discuss the role, regulation and management of serum phosphate in chronic kidney disease, including the efficacies of phosphate binder therapy and dietary interventions.

    • Marc G. Vervloet
    • , Siren Sezer
    • , Ziad A. Massy
    • , Lina Johansson
    • , Mario Cozzolino
    • , Denis Fouque
    •  & on behalf of the ERA–EDTA Working Group on Chronic Kidney Disease–Mineral and Bone Disorders and the European Renal Nutrition Working Group

News and Comment